Table 2.
Agents targeting angiogenesis in GI cancers
| Agents | Tumor types | Regimen | Study Design | References |
| Monoclonal antibodies | ||||
| Bevacizumab | Colorectal cancer | Bevacizumab/IFL | Phase III | [10] |
| Bevacizumab/FOLFOX (E3200) | Phase III | [99] | ||
| Bevacizumab/FOLFIRI | Phase II | [102] | ||
| Pancreatic cancer | Bevacizumab/gemcitabine | Phase II/III | [103] | |
| Bevacizumab/gemcitabine/oxaliplatin | Phase II | [105] | ||
| Bevacizumab/capecitabine/RT | PhaseI | [124] | ||
| VEGF decoy | ||||
| VEGF-Trap | Solid tumors | I-LV5FU2/ VEGF-Trap | PhaseI | [111] |
| Solid tumors | FOLFOX4/ VEGF-Trap | PhaseI | [112] | |
| Tyrosine kinase inhibitors | ||||
| Sorafenib | Hepatocellular carcinoma | Sorafenib | Phase III | [8] |
| Pancreatic cancer | Gencitabine/sorafenib | PhaseI | [116] | |
| Colorectal cancer | Oxaliplatin/sorafenib | PhaseI | [115] | |
| Sunitinib | Colorectal cancer | Irinotecan/cetuximab/sunitinib | PhaseI/II | [122] |
| Hepatocellular carcinoma | Sunitinib | PhaseI/II | [121,123] |
IFL: Irinotecan/leucovorin/bolus fluorouracil; FOLFOX: Oxaliplatin/leucovorin/infusional fluorouracil; FOLFIRI: Irinotecan/leucovorin/infusional fluorouracil; RT: Radiation therapy.